

Treatment Naïve and Treatment Experienced

# Sofosbuvir-Ledipasvir +/- Ribavirin in GT-1 ION Trials

Source: Gilead Sciences, Inc

# Sofosbuvir-Ledipasvir Fixed-Dose Combination +/- RBV

## ION-1, ION-2, and ION-3

Study	Population	Treatment	Duration	SVR 12 Rates
ION-1 (n= 865)	GT-1 Treatment-naïve (15.7% with cirrhosis)	SOF/LDV	12 weeks	97.7% (209/214)
		SOF/LDV + RBV	12 weeks	97.2% (211/217)
		SOF/LDV	24 weeks	NA (n = 217)
		SOF/LDV + RBV	24 weeks	NA (n = 217)
ION-2 (n= 440)	GT-1 Treatment-experienced (20.0% with cirrhosis)	SOF/LDV	12 weeks	93.6% (102/109)
		SOF/LDV + RBV	12 weeks	96.4% (107/111)
		SOF/LDV	24 weeks	99.1% (108/109)
		SOF/LDV + RBV	24 weeks	99.1% (110/111)
ION-3 (n= 647)	GT-1 Treatment-naïve (0.0% with cirrhosis)	SOF/LDV	8 weeks	94.0% (202/215)
		SOF/LDV + RBV	8 weeks	93.1% (201/216)
		SOF/LDV	12 weeks	95.4% (206/216)

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.